{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:33:28Z","timestamp":1765812808703,"version":"3.48.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00415-025-13480-8","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:48:00Z","timestamp":1762602480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study"],"prefix":"10.1007","volume":"272","clinical-trial-number":[{"clinical-trial-number":"nct03971422","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5546-0221","authenticated-orcid":false,"given":"Carolina","family":"Barnett-Tapia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Cort\u00e9s Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Pascuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos","family":"Bloemers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Grimson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tha\u00efs","family":"Taranc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the MycarinG study investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"issue":"1","key":"13480_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"13480_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M, Broderick L, Law N, Barnett C (2023) Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther 12(1):107\u2013128. https:\/\/doi.org\/10.1007\/s40120-022-00408-x","journal-title":"Neurol Ther"},{"issue":"2","key":"13480_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","volume":"36","author":"C Barnett","year":"2018","unstructured":"Barnett C, Herbelin L, Dimachkie MM, Barohn RJ (2018) Measuring clinical treatment response in myasthenia gravis. Neurol Clin 36(2):339\u2013353. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.006","journal-title":"Neurol Clin"},{"issue":"7","key":"13480_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16280","volume":"31","author":"A Meisel","year":"2024","unstructured":"Meisel A, Sacc\u00e0 F, Spillane J, Vissing J (2024) Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis. Eur J Neurol 31(7):e16280. https:\/\/doi.org\/10.1111\/ene.16280","journal-title":"Eur J Neurol"},{"issue":"7","key":"13480_CR5","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia Gravis Activities of Daily Living profile. Neurology 52(7):1487\u20131489. https:\/\/doi.org\/10.1212\/wnl.52.7.1487","journal-title":"Neurology"},{"issue":"6","key":"13480_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA (2022) Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve 65(6):630\u2013639. https:\/\/doi.org\/10.1002\/mus.27476","journal-title":"Muscle Nerve"},{"key":"13480_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW (1998) Reliability testing of the Quantitative Myasthenia Gravis score. Ann N Y Acad Sci 841:769\u2013772. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb11015.x","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"13480_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1212\/wnl.0000000000207278","volume":"101","author":"JT Guptill","year":"2023","unstructured":"Guptill JT, Benatar M, Granit V, Habib AA, Howard JF Jr, Barnett-Tapia C, Nowak RJ et al (2023) Addressing outcome measure variability in myasthenia gravis clinical trials. Neurology 101(10):442\u2013451. https:\/\/doi.org\/10.1212\/wnl.0000000000207278","journal-title":"Neurology"},{"issue":"1","key":"13480_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/mus.28417","volume":"72","author":"K Ruzhansky","year":"2025","unstructured":"Ruzhansky K, Li Y, Wolfe GI, Muppidi S, Guptill JT, Hehir MK, Dimachkie MM et al (2025) Standardization of myasthenia gravis outcome measures in clinical practice: a report of the MGFA task force. Muscle Nerve 72(1):56\u201365. https:\/\/doi.org\/10.1002\/mus.28417","journal-title":"Muscle Nerve"},{"issue":"5","key":"13480_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098089","volume":"9","author":"C Barnett","year":"2014","unstructured":"Barnett C, Bril V, Kapral M, Kulkarni A, Davis AM (2014) A conceptual framework for evaluating impairments in myasthenia gravis. PLoS ONE 9(5):e98089. https:\/\/doi.org\/10.1371\/journal.pone.0098089","journal-title":"PLoS ONE"},{"issue":"9","key":"13480_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/wnl.0000000000002971","volume":"87","author":"C Barnett","year":"2016","unstructured":"Barnett C, Bril V, Kapral M, Kulkarni A, Davis AM (2016) Development and validation of the Myasthenia Gravis Impairment Index. Neurology 87(9):879\u2013886. https:\/\/doi.org\/10.1212\/wnl.0000000000002971","journal-title":"Neurology"},{"key":"13480_CR12","unstructured":"ClinicalTrials.gov. NCT05067348. https:\/\/clinicaltrials.gov\/study\/NCT05067348. Accessed January 2025."},{"key":"13480_CR13","unstructured":"ClinicalTrials.gov. NCT05919407. https:\/\/clinicaltrials.gov\/study\/NCT05919407. Accessed January 2025."},{"key":"13480_CR14","unstructured":"ClinicalTrials.gov. NCT06587867. https:\/\/clinicaltrials.gov\/study\/NCT06587867. Accessed January 2025."},{"key":"13480_CR15","unstructured":"ClinicalTrials.gov. NCT06558279. https:\/\/clinicaltrials.gov\/study\/NCT06558279. Accessed January 2025."},{"issue":"2","key":"13480_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/ene.14547","volume":"28","author":"M Alcantara","year":"2021","unstructured":"Alcantara M, Sarpong E, Barnett C, Katzberg H, Bril V (2021) Chronic immunoglobulin maintenance therapy in myasthenia gravis. Eur J Neurol 28(2):639\u2013646. https:\/\/doi.org\/10.1111\/ene.14547","journal-title":"Eur J Neurol"},{"issue":"6","key":"13480_CR17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mus.27243","volume":"63","author":"D Menon","year":"2021","unstructured":"Menon D, Alnajjar S, Barnett C, Vijayan J, Katzberg H, Fathi D, Alcantara M et al (2021) Telephone consultation for myasthenia gravis care during the COVID-19 pandemic: assessment of a novel virtual myasthenia gravis index. Muscle Nerve 63(6):831\u2013836. https:\/\/doi.org\/10.1002\/mus.27243","journal-title":"Muscle Nerve"},{"issue":"4","key":"13480_CR18","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mus.27369","volume":"64","author":"J Vijayan","year":"2021","unstructured":"Vijayan J, Menon D, Barnett C, Katzberg H, Lovblom LE, Bril V (2021) Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis. Muscle Nerve 64(4):462\u2013466. https:\/\/doi.org\/10.1002\/mus.27369","journal-title":"Muscle Nerve"},{"issue":"5","key":"13480_CR19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/mus.27657","volume":"66","author":"A Urra Pincheira","year":"2022","unstructured":"Urra Pincheira A, Alnajjar S, Katzberg H, Barnett C, Daniyal L, Rohan R, Bril V (2022) Retrospective study on the safety of COVID-19 vaccination in myasthenia gravis. Muscle Nerve 66(5):558\u2013561. https:\/\/doi.org\/10.1002\/mus.27657","journal-title":"Muscle Nerve"},{"issue":"1","key":"13480_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16022","volume":"31","author":"R Martinez-Harms","year":"2024","unstructured":"Martinez-Harms R, Barnett C, Alcantara M, Bril V (2024) Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis. Eur J Neurol 31(1):e16022. https:\/\/doi.org\/10.1111\/ene.16022","journal-title":"Eur J Neurol"},{"issue":"3","key":"13480_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3233\/jnd-200484","volume":"7","author":"RHP de Meel","year":"2020","unstructured":"de Meel RHP, Barnett C, Bril V, Tannemaat MR, Verschuuren JJGM (2020) Myasthenia Gravis Impairment Index: sensitivity for change in generalized muscle weakness. J Neuromuscul Dis 7(3):297\u2013300. https:\/\/doi.org\/10.3233\/jnd-200484","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"13480_CR22","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s10072-021-05585-5","volume":"43","author":"F Pasqualin","year":"2022","unstructured":"Pasqualin F, Barnett C, Guidoni SV, Albertini E, Ermani M, Bonifati DM (2022) Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII). Neurol Sci 43(3):2059\u20132064. https:\/\/doi.org\/10.1007\/s10072-021-05585-5","journal-title":"Neurol Sci"},{"issue":"5","key":"13480_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22(5):383\u2013394. https:\/\/doi.org\/10.1016\/s1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"issue":"7","key":"13480_CR24","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/19420862.2018.1505464","volume":"10","author":"B Smith","year":"2018","unstructured":"Smith B, Kiessling A, Lledo-Garcia R, Dixon KL, Christodoulou L, Catley MC, Atherfold P et al (2018) Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs 10(7):1111\u20131130. https:\/\/doi.org\/10.1080\/19420862.2018.1505464","journal-title":"MAbs"},{"issue":"23","key":"13480_CR25","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1212\/wnl.0000000000004676","volume":"89","author":"C Barnett","year":"2017","unstructured":"Barnett C, Bril V, Kapral M, Kulkarni AV, Davis AM (2017) Myasthenia Gravis Impairment Index: responsiveness, meaningful change, and relative efficiency. Neurology 89(23):2357\u20132364. https:\/\/doi.org\/10.1212\/wnl.0000000000004676","journal-title":"Neurology"},{"issue":"12","key":"13480_CR26","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/wnl.0000000000010574","volume":"95","author":"M Mendoza","year":"2020","unstructured":"Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C (2020) Patient-acceptable symptom states in myasthenia gravis. Neurology 95(12):e1617\u2013e1628. https:\/\/doi.org\/10.1212\/wnl.0000000000010574","journal-title":"Neurology"},{"issue":"2","key":"13480_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102\u2013109. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.012","journal-title":"J Clin Epidemiol"},{"key":"13480_CR28","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum Associates, New Jersey, US","edition":"2"},{"issue":"8","key":"13480_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","volume":"30","author":"AM Ruiter","year":"2020","unstructured":"Ruiter AM, Verschuuren JJGM, Tannemaat MR (2020) Fatigue in patients with myasthenia gravis. a systematic review of the literature. Neuromuscul Disord 30(8):631\u2013639. https:\/\/doi.org\/10.1016\/j.nmd.2020.06.010","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"13480_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s13023-021-02064-0","volume":"16","author":"S Cleanthous","year":"2021","unstructured":"Cleanthous S, Mork AC, Regnault A, Cano S, Kaminski HJ, Morel T (2021) Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet J Rare Dis 16(1):457. https:\/\/doi.org\/10.1186\/s13023-021-02064-0","journal-title":"Orphanet J Rare Dis"},{"key":"13480_CR31","doi-asserted-by":"publisher","first-page":"1368525","DOI":"10.3389\/fneur.2024.1368525","volume":"15","author":"A Regnault","year":"2024","unstructured":"Regnault A, Habib AA, Creel K, Kaminski HJ, Morel T (2024) Clinical meaningfulness and psychometric robustness of the MG Symptoms PRO scales in clinical trials in adults with myasthenia gravis. Front Neurol 15:1368525. https:\/\/doi.org\/10.3389\/fneur.2024.1368525","journal-title":"Front Neurol"},{"issue":"6","key":"13480_CR32","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1007\/s00415-021-10902-1","volume":"269","author":"LK Andersen","year":"2022","unstructured":"Andersen LK, Jakobsson AS, Revsbech KL, Vissing J (2022) Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. J Neurol 269(6):3086\u20133093. https:\/\/doi.org\/10.1007\/s00415-021-10902-1","journal-title":"J Neurol"},{"key":"13480_CR33","doi-asserted-by":"publisher","first-page":"1187189","DOI":"10.3389\/fneur.2023.1187189","volume":"14","author":"R Martinez-Harms","year":"2023","unstructured":"Martinez-Harms R, Barnett C, Bril V (2023) Time to achieve a patient acceptable symptom state in myasthenia gravis. Front Neurol 14:1187189. https:\/\/doi.org\/10.3389\/fneur.2023.1187189","journal-title":"Front Neurol"},{"key":"13480_CR34","doi-asserted-by":"publisher","first-page":"1502721","DOI":"10.3389\/fimmu.2024.1502721","volume":"15","author":"G Watanabe","year":"2024","unstructured":"Watanabe G, Takai Y, Nagane Y, Kubota T, Yasuda M, Akamine H, Onishi Y et al (2024) Cutoffs on severity metrics for minimal manifestations or better status in patients with generalized myasthenia gravis. Front Immunol 15:1502721. https:\/\/doi.org\/10.3389\/fimmu.2024.1502721","journal-title":"Front Immunol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13480-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:29:37Z","timestamp":1765812577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13480-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["13480"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13480-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carolina Barnett-Tapia has served as a paid Consultant for Alexion Pharmaceuticals, argenx, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Novartis and UCB. She has received research support from MGNet, Muscular Dystrophy Canada and the US Department of Defense. She is the primary developer of the MGII and may receive royalties for its use. Elena Cort\u00e9s Vicente receives public speaking honoraria and compensation for advisory boards and\/or consultation fees from Alexion Pharmaceuticals, argenx, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine) and UCB. Robert M. Pascuzzi is Professor Emeritus of Neurology at Indiana University and receives compensation for his professional work from Indiana University Health. He has no financial relationship with any pharmaceutical company and receives no compensation from any pharmaceutical company (present or past). Robert M. Pascuzzi speaks at educational seminars on a broad variety of general neurology topics for primary care physicians through the organization Medical Education Resources (an educational organization with no links or ties to any pharmaceutical or healthcare business company). Therefore, Robert M. Pascuzzi has no conflicts of interest related to this research, manuscript, presentation, or publication. Kimiaki Utsugisawa has served as a paid Consultant for argenx, Chugai Pharmaceutical, HanAll Biopharma, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Merck, Mitsubishi Tanabe Pharma, UCB and Viela Bio (now Amgen); he has received speaker honoraria from Alexion Pharmaceuticals, argenx, the Japan Blood Products Organization and UCB. Jos Bloemers is an employee and shareholder of UCB. Fiona Grimson is an employee and shareholder of UCB. Tha\u00efs Taranc\u00f3n is an employee and shareholder of UCB. Vera Bril is a Consultant for Akcea, Alexion Pharmaceuticals, Alnylam, argenx, CSL, Grifols, Immunovant, Ionis, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Momenta (now Johnson & Johnson), Novo Nordisk, Octapharma, Pfizer, Powell Mansfield, Roche, Sanofi, Takeda Pharmaceuticals and UCB. She has received research support from Akcea, Alexion Pharmaceuticals, argenx, CSL, Grifols, Immunovant, Ionis, Momenta (now Johnson & Johnson), Octapharma, Takeda Pharmaceuticals, UCB and Viela Bio (now Amgen).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki. A national, regional or independent ethics committee or institutional review board (depending on site) approved the protocol. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"752"}}